SOPHIA GENETICS SA (SOPH)
CH1125843347 - Common Stock
We assign a fundamental rating of 3 out of 10 to SOPH. SOPH was compared to 39 industry peers in the Health Care Technology industry. While SOPH seems to be doing ok healthwise, there are quite some concerns on its profitability. SOPH shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
SOPH had negative earnings in the past year.
In the past year SOPH has reported a negative cash flow from operations.
SOPH had negative earnings in each of the past 5 years.
In the past 5 years SOPH always reported negative operating cash flow.
1.2 Ratios
SOPH has a Return On Assets (-36.88%) which is comparable to the rest of the industry.
SOPH's Return On Equity of -54.99% is in line compared to the rest of the industry. SOPH outperforms 52.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.88% | ||
| ROE | -54.99% | ||
| ROIC | N/A |
ROA(3y)-32.4%
ROA(5y)-38.47%
ROE(3y)-40.87%
ROE(5y)-62.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SOPH has a better Gross Margin (68.30%) than 65.79% of its industry peers.
SOPH's Gross Margin has improved in the last couple of years.
SOPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.37%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SOPH has more shares outstanding
SOPH has a worse debt/assets ratio than last year.
2.2 Solvency
SOPH has an Altman-Z score of -0.35. This is a bad value and indicates that SOPH is not financially healthy and even has some risk of bankruptcy.
SOPH has a Altman-Z score (-0.35) which is comparable to the rest of the industry.
SOPH has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
SOPH has a Debt to Equity ratio of 0.23. This is comparable to the rest of the industry: SOPH outperforms 52.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.35 |
ROIC/WACCN/A
WACC4.9%
2.3 Liquidity
A Current Ratio of 4.40 indicates that SOPH has no problem at all paying its short term obligations.
SOPH has a Current ratio of 4.40. This is amongst the best in the industry. SOPH outperforms 81.58% of its industry peers.
A Quick Ratio of 4.17 indicates that SOPH has no problem at all paying its short term obligations.
SOPH has a Quick ratio of 4.17. This is in the better half of the industry: SOPH outperforms 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.4 | ||
| Quick Ratio | 4.17 |
3. Growth
3.1 Past
SOPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.07%, which is quite good.
SOPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.14%.
The Revenue has been growing by 29.98% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.3%
Revenue 1Y (TTM)20.14%
Revenue growth 3Y29.98%
Revenue growth 5YN/A
Sales Q2Q%5.01%
3.2 Future
SOPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.44% yearly.
SOPH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.44% yearly.
EPS Next Y24.55%
EPS Next 2Y14.83%
EPS Next 3Y11.44%
EPS Next 5YN/A
Revenue Next Year5.51%
Revenue Next 2Y12.91%
Revenue Next 3Y17.61%
Revenue Next 5Y28.44%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SOPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.83%
EPS Next 3Y11.44%
5. Dividend
5.1 Amount
No dividends for SOPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOPHIA GENETICS SA
NASDAQ:SOPH (9/18/2024, 8:00:03 PM)
4.37
+0.39 (+9.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap289.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.88% | ||
| ROE | -54.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.4 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)12.07%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y24.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.14%
Revenue growth 3Y29.98%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y